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Abstract: An efficient and high yielding process for the production of impurity free rivaroxaban (1), an anti-
coagulant agent using alternate synthon is reported. The key components of the process involve; synthesis of 
4-(4-aminophenyl)-3-morpholinone (5) using easily available inexpensive nitro aniline (17), condensation of 
4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride (9) with alternate 
synthon 4-nitrophenyl 5-chlorothiophene-2-carboxylate (11) in dimethylsulfoxide (DMSO) as a solvent and 
triethylamine as a base and isolation of the rivaroxaban (1) by designing the crystallization in same reaction pot 
using specific combination of acetonitrile and methanol as anti-solvents to obtain highly pure rivaroxaban (1) with 
desired ploymorphic form with an overall yield of around 22% (Calculated from 17). The developed process avoids 
the use of hazardous chemicals, critical operations and tedious work-ups. Potential impurities arouse during the 
reaction at various stages and carry-over impurities from starting materials were controlled selectively by design-
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Background
Rivaroxaban (1), chemically known as 5-chloro-N-({(5S)-
2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazoli-
din-5-yl}methyl)thiophene-2-carboxamide is an orally 
active direct factor Xa (FXa) inhibitor drug developed 
by Bayer and approved by United states Food and Drug 
Administration (USFDA) during July 2011 under the 
trade name of Xarelto [1, 2]. Rivaroxaban (1) used for the 
prevention and treatment of various thromboembolic 
diseases, in particular pulmonary embolism, deep venous 
thrombosis, myocardial infarction, angina pectoris, reoc-
clusion and restenosis after angioplasty or aortocoronary 
bypass, cerebral stroke, transitory ischemic attacks, and 
peripheral arterial occlusive diseases [1–4].
Alexander and co-workers [3, 4] reported first synthesis 
of 1 using linear approach that involves condensation of 
morpholin-3-one (2) with fluoro nitrobenzene (3) using 
sodium hydride as a base in N-methylpyrrolidone (NMP) 
to get nitro morpholinone (4), nitro group of 4 was 
reduced using palladium on carbon (Pd–C) and hydrogen 
in tetrahydrofuran (THF) to achieve 4-(4-aminophenyl)-
3-morpholinone (5) which was then condensed with 
2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1, 3(2H)-dione 
(6) in ethanol and water mixture to provide amino alco-
hol 7. Cyclization of 7 using N,N′-carbonyldiimidazole 
(CDI) in presence of 4-dimethylaminopyridine (DMAP) 
in THF furnished 2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-
4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-
1,3(2H)-dione (8). Deprotection of 8 using methyl amine 
in ethanol followed by condensation of obtained 9 with 
5-chlorothiophene-2-carbonyl chloride (10) in pyridine 
furnished rivaroxaban (1) with an overall yield of 4.5% 
starting from compound 2 (Scheme 1).
The disclosed process has several disadvantages such 
as: (a) use of highly pyrophoric reagent like sodium 
hydride, (b) excess loading of expensive key raw mate-
rial 6 and CDI that generate excess amount of by-product 
imidazole and makes the process economically and envi-
ronmentally inefficient, (c) repeated filtrations involved 
for the isolation of 7 decreases the production through-
put, (d) use of highly flammable solvent like diethyl ether 
for washing the compound 7 and hazard and toxic sol-
vent like pyridine for the reaction at API stage makes the 
process unsafe, (e) purification of 1, 4, 5 and 8 by column 
chromatography makes process lengthy and time con-
suming, (f ) incomplete conversion of intermediates leads 
to formation of many process related impurities, and (g) 
low overall yield of 4.5% starting from compound 2 which 
makes process less viable for commercial production.
Rafecas et  al. [5] disclosed process for the prepa-
ration of rivaroxaban (1) and intermediates thereof 
(Scheme 2) with an overall yield of 5.93 with 98.4% purity 
by HPLC. Silvo et  al. in 2011 reported the purification 
of rivaroxaban (1) by solvent mediated crystallization 
process [6] using various solvents and/or solvent com-
binations to provide maximum of around 99.70% purity 
by HPLC with a loss of around 10–20% yield making 
the process expensive. Several other processes reported 
in the literature also suffer disadvantages similar to as 
described above and thus makes the process unsuitable 
for large scale production [7–19].
We hereby report an efficient, economic, scalable, 
impurity-free and production friendly process for the 
synthesis of rivaroxaban (1) which allows direct isolation 
of API from reaction mass without further purification 
complying with ICH quality [20] and desired polymor-
phic form [21, 22]. Rivaroxaban (1) was obtained from 17 
in seven steps with an overall yield of 22% and purity of 
99.85% by HPLC using commercially available and less 
expensive raw materials and reagents.
Results and discussion
Process research and development of rivaroxaban mainly 
focused on following three aspects: (a) to develop an 
improved and high yielding process for the manufacture 
of 9 starting from 17 without the use of column chroma-
tographic purification and avoiding the hazardous and 
unsafe chemical reagents and solvents, (b) to develop an 
efficient process for the manufacture of 1 starting from 
9 which reduces the formation of impurities and provide 
high reaction yield and (c) to achieve crystallization and 
isolation of 1 with ICH quality and desired polymorphic 
form (modification-I) [21] directly from reaction mass 
from the same pot without subjecting the crude to a fur-
ther purification.
(a) Efficient process for the preparation of compound 9
Critical and cost-contributing intermediate 5 was pre-
pared [23] using easily available inexpensive nitro aniline 
(17) as a starting material. Boric acid catalyzed conden-
sation of 17 with 2-(2-chloroethoxy) acetic acid in tolu-
ene followed by cyclization of the obtained chloroamide 
18 in sodium hydroxide in the presence of phase trans-
fer catalyst tetra-butyl ammonium bromide (TBAB) 
provided nitro compound 19. Catalytic reduction of 19 
using Pd–C as catalyst and H2 gas or ammonium for-
mate as a source of hydrogen in methanol provided key 
intermediate 5 (Scheme 3). However, another key inter-
mediate compound 6 was prepared as per the literature 
procedure with little process improvements.
Preparation of amino alcohol 7 (Scheme 3) by nucleo-
philic attack of 5 on oxirane 6 has been attempted using 
various solvents. Among several solvents screened such 
as methanol, ethanol, IPA, DMF, DMSO, toluene, water, 
acetonitrile, ethyl acetate, THF and their mixtures, the 
mixture of IPA and water found to be the suitable solvent 
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for this reaction. It was noticed that oxirane 6 underwent 
degradation in other solvents except IPA–water result-
ing into unreacted 5 in the reaction. It was also noticed 
that excess use of oxirane 6 results into the formation of 
dimer impurity 16 (determined by LC–MS). Further, it 
has also been observed that oxirane 6 found to be stable 
in IPA–water mixture and thus reaction goes to com-
pletion with 1.05  mol equivalents of oxirane 6 at 80°C 
to provide 7 with negligible quantities of dimer 16. The 
precipitated compound 7 was isolated by filtering and 
drying the product under vacuum at 60–65°C for 5–6 h 
with 95% yield and 97.0% purity by HPLC. During opti-
mization, specific ratio of IPA and water (17:3) found to 
be optimum to provide excellent yield and quality of 7 
(Table 1).
Amino alcohol 7 obtained was then treated with CDI 
to achieve oxazolidinone 8 without further purification. 
The reaction was explored in various solvents (toluene, 
THF, ethyl acetate, 2-Me-THF, DCM and acetonitrile) 
using different bases (K2CO3, Na2CO3, DIPEA, TEA and 
NaHCO3). During screening experiments incomplete 
conversion of 7 was observed in various solvents and dif-
ferent bases after prolonged maintenance at various tem-
perature conditions resulting into the formation of many 
side products. However, reaction in DCM in the pres-
ence of K2CO3 as a base at 25–30°C proceeded smoothly 
with a reduced amount of impurities (∼0.5% by HPLC). 
Work-up involves the filtration of the reaction mass to 
separate inorganic solids, concentration of the DCM and 













































































H2/ Pd-C/ THF/ 
EA/ Hexane














Dichloro impurity Deschloro impurity
Scheme 1 Reported synthetic scheme for rivaroxaban (1) as per basic patent US 7576111.
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a white crystalline solid with 99.8% purity by HPLC and 
95% yield.
Synthesis of key intermediate 9 (Scheme  3) was then 
achieved by deprotection of 8 using 40% aqueous methyl 
amine solution in methanol at 60–65°C. After the reac-
tion is completed the reaction mass was cooled gradually 
to 25–30°C and conc. HCl was added slowly to the mass 
to obtain HCl salt of 9 as white crystalline solid with 
90% yield and 99.0% purity by HPLC. Many by-products 
and analogous impurities formed during the deprotec-
tion reaction were identified by LC–MS in reaction mass 
as well as in the isolated solid (Figure  1). Based on the 
understanding of impurities purification has been estab-
lished by recrystallization using methanol and DCM to 
eliminate these impurities. Traces of these impurities if 
left behind at this stage will be carried forward with 9 to 
impact the purity of rivaroxaban (1) thus it is necessary to 
eliminate at this step. It was also experienced that these 
impurities were found to be difficult to remove from the 
product and ultimately require column chromatographic 
purifications. The data of the pilot batches along with the 
impurity details are presented in Table 2.
(b) Novel and efficient process for the preparation 
of rivaroxaban (1)
Our next objective was to establish the process for the con-
densation of pure 9 with 5-chlorothiophene-2-carboxylic 
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Scheme 2 Reported synthetic scheme for rivaroxaban (1) as per WO/2011 080341.
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Scheme 3 Alternate and efficient synthesis of rivaroxaban (1).
Table 1 Impact of IPA–water ratio on nucleophilic substitution reaction between 5 and 6 to give 7
NI not isolated.
a Reaction not progressed.
b Reaction mass not stirrable.
c OXI (6) could not be removed in water.
d Thick reaction mass, unable to transfer from reaction flask to centrifuge.
Expt.  
no.
Compd. 6  
(mole. eq. w. r. to 5)
Volume w.r.to 5 Yield  
(%)
HPLC purity  
(%)
Content of 5 and 6
IPA Water 5 (%) 6 (%)
1a 1.05 10 – NI 62.00 12.00 10.0
2b,c,d 1.05 – 10 78.00 86.90 0.57 6.00
3b,d 1.05 9 1 90.00 94.38 1.70 2.00
4b,d 1.05 13.5 1.5 87.80 97.50 0.66 0.70
5 1.05 17 3 91.00 97.18 0.60 0.40
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or no impurities in the reaction mass itself. We observed 
that reaction of 9 with 5-chlorothiophene-2-carbonyl 
chloride (10) as pre reported was incomplete leading to 
presence of unreacted starting material with few degraded 
impurities both in the reaction mass and isolated product 
1. To overcome the issue we identified three alternative 
synthons (Scheme 4) such as active ester 11, aldehyde 12 
and alcohol 13 as the counterpart to react with 9 instead of 
10 to explore improved or efficient reaction profile. During 
the exploration of the experiments to check the feasibility 
of each of these options interesting results were noticed 
which are tabulated in Table 3.
Among the three synthons identified (11–13), active 
ester 11 as a substrate found to be the most promis-
ing synthon to react with 9 as the reaction underwent 
selectively and cleanly without formation of any impuri-
ties whereas in case of route-B and C, though oxidative 
amidation proceeded well via an imine intermediate (17, 
Scheme 4) but lead to the formation of many impurities 
with poor yields and hence discontinued. Thus route-A 
has been selected for further optimization.
Further, the situation was highly demanding to design 
the experiment for the synthesis of 1 which will directly 
yield ICH quality API from the reaction without any 
further purification of crude compound. In such a situ-
ation, the selection of suitable solvent and base was very 
important to achieve the target. Since the solubility of 1 
is very low in most of the solvents except DMSO, DMF, 
NMP and acetic acid, we have selected DMSO and DMF 
as a reaction solvent for further screening based on the 
results of initial screen.
During the process optimization though the reaction of 
9 with 11 progressed well with inorganic bases, filtration 
of the reaction mass to remove the inorganic base was 
not possible because the product is also precipitated out 
in the reaction mass as the reaction progresses. Alterna-
tively, removing the inorganic base by adding water into 
the reaction mass and isolating the product found to pos-
sess several impurities which were difficult to remove 
even after repeated crystallizations. Thus we restricted 
our selection criteria to organic bases which are miscible 
with the selected solvents. Further, the solvents for the 
reaction were selected in which both organic base as well 
as rivaroxaban (1) is soluble.
Complete conversion 9 to 1 was observed when DMF 
or DMSO was used as a solvent in presence of trieth-
ylamine (TEA) as a base at 40°C. Though the reaction 
profile was same both in DMF and DMSO, we have 
chosen DMSO as it is a class-3 solvent whereas DMF is 
class-2 solvent. At the end of the reaction, the reaction 
mass was in a complete dissolved state and anti-solvent 
mediated crystallization shall be designed. Accordingly 
MeOH, IPA, ACN, ethyl acetate, acetone, THF, water, 
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Figure 1 Identified impurities in the reaction mass of 9 by LC–MS. By-products and impurities formed during the deprotection of phthalimide 
group in 8 to form 9 by LC–MS in reaction mass as well as in the isolated solid of compound 9.
Table 2 Yield and quality data of amine compound 9 from scale-up batches
ND not detected.
No. Comp 8 (kg) MeNH2 sol. (L) MeOH (L) Temp (°C) Yield (%) Quality details by HPLC (%)
9 8 7 6 5 16
1 2.88 2.93 28.8 60–65 87.5 99.76 ND 0.04 ND ND ND
2 2.87 2.92 28.7 60–65 86.0 99.80 ND 0.02 ND ND ND
3 2.90 2.95 29.0 60–65 85.0 99.86 0.01 0.02 ND ND ND
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crystallize out the product with desired quality, yield and 
polymorph. The details of the same are summarized in 
Table 4.
When DMSO as solvent and methanol as anti-sol-
vent are used the rivaroxaban 1 was precipitated out 
with a good yield but failed to eliminate dichloro impu-
rity 14 and deschloro impurity 15. When acetonitrile is 
used as an anti-solvent, impurities 14 and 15 were con-
trolled well below 0.10% with good yield and purity of 
1 (Scheme  1). Thus acetonitrile has been selected as an 
antisolvent for further optimization of the crystallization 
process. Alternatively source of these impurities (14 and 
15) were further controlled in synthon 11.
Mechanistically, the neucleophilic attack of amine 9 on 
active ester 11 was very facile because of the good leav-
ing group (p-nitrophenol) on the electrophilic carbon 
of 11 that favored the progress of reaction without any 
side reaction. The by-product p-nitrophenol generated 
in the reaction was washed away with the mother liquors 
during the filtration. The content of p-nitrophenol in 
the pure 1 was measured using HPLC and found below 
75 ppm in all the batches produced.
(c) Crystallization and isolation of 1 from the reaction pot
After the completion of reaction in DMSO at 40°C the 
temperature of the reaction mass was raised to 60°C and 
acetonitrile was added at same temperature and cooled 
gradually to 20–25°C to obtain the crystalline solid. The 
solid was filtered, washed with chilled acetonitrile and 
dried under vacuum to provide 1 with 75% yield and 
99.8% purity with desired polymorph (Modification 1). 
Upon detailed analysis, it was learnt that the isolated 
solid was failed in residual solvent test by GC-HS with 
respect to acetonitrile content. The content of ACN by 
GC-HS was around 2,000  ppm against its acceptable 
limit of 410  ppm [20]. Different industrial techniques 
such as prolonged drying under vacuum, air tray drying, 












































80 oC/ 5h/ 34.5%
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KI/ TBHP/ ACN/
75 oC/ 23 h
DMSO/ TEA/ ACN/
MeOH/ 40 oC/ 1h/ 86%
17
Scheme 4 Synthesis of 1 using coupling of different synthons 11, 12 and 13 with 9.
Table 3 Results obtained from different routes (A, B and C) for synthesis of 1
NA not analyzed, NI not isolated.
Route Compd. 9 (g) Substrate  
(mol. eq.)
Solvents Time (h) Temp (°C) HPLC purity (%) Yield (%)
Reaction mass Isolated solid
A 10.0 11 (1.05) DMSO 1.0 40 78.0 99.85 86.0
B 10.0 12 (1.20) ACN 5.0 80 60.8 91.0 34.5
C 10.0 13 (1.50) ACN 23.0 75 NA 67.17 NI
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temperatures, intermittent milling of the crystals fol-
lowed by drying were tested to remove the acetonitrile 
content but none of these techniques were successful.
Observations of the crystallization process were thor-
oughly investigated to understand theory of nucleation 
and crystal growth in the reaction flask to overcome the 
issue of high residual content in the crystals. Detailed 
observation of the process provided the following insight 
on the crystallization viz., (1) Solution Reaction mass 
at 60°C to provide the clear solution indicating that the 
product is in the soluble state, (2) Saturation Acetonitrile 
was added as anti-solvent at 60°C to achieve the saturated 
solution, (3) Super saturation The saturated solution was 
gradually cooled to 20–25°C to achieve super satura-
tion which lead to nucleation and crystal growth. It was 
presumed that the nucleation and growth of crystals are 
occurring under acetonitrile environment. As the con-
centration of acetonitrile was more than that of DMSO 
which could get trapped into the crystal lattice during 
the primary nucleation and continued to do so as the 
crystal growth continues. Thus, we envisaged that if we 
limit the contact of acetonitrile during nucleation step 
by reducing its volume and/or by introducing the third 
anti solvent during crystal formation/nucleation pro-
cess, the entrance of solvent into the crystal lattice may 
be arrested. Accordingly, different set of solvents were 
screened as a third solvent along with acetonitrile. As per 
our assumption, methanol has given an excellent result in 
controlling the residual solvent content as a third solvent 
among the many screened. Further the ratio of first anti 
solvent (ACN) and second anti solvent (methanol) played 
a tremendous impact on the quality and yield (Table 5).
Table 4 Trend data of yield and impurity profile of 1 in different reaction solvents/anti-solvents
NP Nitrophenol, NI not isolated, ND not detected.
Expt. no. Reaction solvent Base Anti solvents Yield (%) HPLC purity (%) Impurity profile by HPLC (%)
9 14 15 NP 11
1 DCM TEA – NI 35.9 41 0.09 0.20 13.3 1.05
2 DMF K2CO3 Water 60 98.84 0.56 0.02 0.10 0.16 0.12
3 DMF TEA Methanol 30 99.65 0.01 0.14 0.09 0.09 ND
4 DMF TEA Ethyl acetate NI 99.62 0.07 0.14 0.08 0.02 ND
5 DMF TEA THF 20.0 99.70 0.07 0.05 0.08 0.02 ND
6 DMSO TEA Methanol 90.0 99.12 ND 0.14 0.22 0.14 ND
7 DMSO TEA IPA NI 98.7 0.20 0.10 0.2 0.23 ND
8 DMSO TEA Acetic acid/water 75.0 97.1 0.04 0.13 0.10 1.78 ND
9 DMSO TEA Water 75.0 98.6 0.43 0.18 0.11 0.12 0.02
10 DMSO TEA Acetonitrile 69.1 99.85 0.01 0.06 0.03 0.01 0.02
11 DMSO TEA Acetonitrile 75.0 99.86 ND 0.07 0.02 0.02 ND
12 DMSO DBU Acetonitrile 75.1 99.70 ND 0.13 0.05 0.02 ND
Table 5 HPLC trend data, yield, and acetonitrile content by GC in 1
ND not detected, NA not analyzed.











Content by HPLC (%) ACN content 
by GC (ppm)
1 14 15 NP 11
1 5 10 – 69.1 99.85 0.06 0.03 0.02 ND 1,980
2 3 8 – 75 99.86 0.07 0.02 0.02 ND 753
3 4 10 – 71 99.51 ND 0.14 ND ND NA
4 4 6 4 71 99.51 0.15 0.03 ND ND 580
5 4 4 6 75.0 99.56 0.06 ND ND ND 256
6 4 6 4 75.1 99.72 0.12 ND 0.02 ND NA
7 4 6 9 80.2 99.68 0.05 ND 0.05 ND 337
8 4 4 6 87 99.79 0.04 0.03 0.03 ND 424
9 4 4 4 – 99.55 0.06 ND 0.01 ND 371
10 4 2 6 – 99.68 0.05 0.04 ND ND 283
11 6 2 6 86.4 99.81 0.04 ND 0.04 ND 110
12 6 2 6 84.2 99.84 0.03 0.02 ND ND 135
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Based on the data the solvent and anti-solvents ratio of 
6:2:6 volumes of DMSO:ACN:MeOH was finalized (entry 
11 and 12, Table 5) to achieve robust process to provide 1 
with yield of 86% and purity of 99.8% by HPLC. The ace-
tonitrile content was achieved below 300 ppm (GC-HS) 
in the final product. The trend data of content of impu-
rities by HPLC and residual solvent content by GC-HS 
from pilot batches is provided in Table 6.
Further, to measure the extent of greenness of newly 
developed process, we have calculated process mass 
intensity (PMI), e-factor and atom economy (calculated 
for last four stages) using the standard calculations pro-
vided in ACS guideline [24] and compared with the origi-
nator’s process. The details are provided in Table 7.
Conclusion
An efficient, economic, and production friendly process 
for the preparation of highly pure rivaroxaban via alter-
nate synthon (11) is described. Reaction and isolation by 
crystallization have been designed in the same pot avoid-
ing the work-up which normally involve extraction, dis-
tillation, separations etc., to provide the rivaroxaban (1) 
meeting the ICH quality and desired polymorphic form 
with an overall yield of 22% is starting from nitro aniline 
(17) over seven stages.
Experimental
All reagents, solvents, and processing aids are commercial 
products and were used as received. For reactions run of 
pilot scale, glass line reactors having variable rate agitation, 
a −10 to 150°C jacket temperature range were used for the 
reaction. 1H NMR spectra was recorded in DMSO-D6 and 
D2O using Varian Gemini 400 MHz FT NMR spectrometer; 
the chemical shifts are reported in δ ppm relative to TMS. 
Related substance purity and residual solvent content in 
solid were monitored by high performance liquid chroma-
tography (HPLC) on Agilent Technologies 1200 series. The 
gas chromatography on Agilent Technologies 7683B with 
head space was used for analyzing the residual solvents.
HPLC method for calculating the chemical purity, chiral 
purity and assay
Related substances, assay and chiral purity of rivaroxaban 
(1) were estimated by a gradient HPLC analysis method 
developed at Megafine.
(a) Related substances and assay of rivaroxaban were 
estimated using Zorbax SB-CN, (250 × 4.6 mm ID), 5 µ 
column; mobile phase A comprising a mixture of phos-
phate buffer (0.01  m potassium dihydrogen orthophos-
phate, 0.005  m 1-heptane sulphonic acid sodium salt, 
triethylamine, and adjust the pH 6.7 using orthophos-
phoric acid). Mobile phase B comprising a mixture of 
acetonitrile/water in the ratio 80:20 (v/v); gradient elu-
tion: time (min)/A (v/v): B (v/v), T0.0/80:20, T5.o/75:25, 
T25.0/50:50, T38.0/50:50, T42.0/80:20, T50.0/80:20; flow rate 
1.5 ml/min column temperature 35°C wavelength 240 nm. 
The observed retention time of rivaroxaban under these 
chromatographic conditions is about 16.0 min.
(b) Chiral purity was estimated using Chiralpak IE 
(250 × 4.6 mm ID), 5 µ column; mobile phase compris-
ing a mixture of n-Hexane, ethanol, methanol, THF 
and ammonia in the ratio of 35:35:15:15:0.1 (v/v/v/v/v) 
respectively; flow rate 1.0  ml/min.; column temperature 
35°C; wavelength 240 nm. The observed retention time of 
(S)-rivaroxaban is about 11.7 min and (R)-rivaroxaban is 
about 10 min.
Table 6 Trend data of residual solvent, HPLC purity and yield of three pilot batches
ND not detected.
Sr. no. Solvent content by GC-HS in ppm HPLC purity (%) Yield (%)
DMSO Acetonitrile Methanol 1 9 11 14 15
1 1,068 238 352 99.81 0.01 ND 0.02 ND 85.2
2 991 226 368 99.81 0.01 ND 0.03 ND 85.3
3 969 241 407 99.83 0.01 ND 0.02 ND 85.9
Table 7 PMI, e-factor, and atom economy of the developed process
By-products and impurities formed during the deprotection of phthalimide group in 8 to form 9 by LC–MS in reaction mass as well as in the isolated solid of 
compound 9.
Process Theoretical PMI Actual PMI Aqueous PMI Solvent PMI e-factor Atom economy
Megafine process 4.13 7.40 2.04 76.6 85.13 37.97
U.S. Pat. 7,576,111 2.24 28.14 25.0 415.3 455.95 44.91
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GC method for calculating residual solvent content
(a) Residual solvents content was estimated using 
DB-624, 60 m, 0.25 mm ID, 1.4 µ film thickness fused 
silica capillary column; detector temperature 280°C; 
injector temperature 250°C; split ratio 10:1; column 
flow 0.8  ml/min; nitrogen used as carrier gas; head 
space conditions: oven temperature 90°C; loop tem-
perature 115°C; Transfer line temperature 120°C. The 
observed elution order of solvents is methanol, iso-
propyl alcohol, acetonitrile, dichloromethane, and 
tetrahydrofuran at RT 9.1, 13.5, 13.9, 14.4 and 18.1, 
respectively.
(b) DMSO was estimated by using HP-5, 30  m, 
0.53  mm ID, 5.0 μ film thickness, Fused silica capillary 
column; detector temperature 280°C; injector tempera-
ture 250°C; split ratio 3:1; column flow 4 psi (at constant 
pressure).; nitrogen used as carrier gas; The observed 
retention time of DMSO is 5.5 min.
Preparation of 2‑(2‑chloroethoxy)‑N‑(4‑nitrophenyl) 
acetamide (18)
A solution of boric acid (13 g, 0.21 mol) and 4-nitroani-
line (17, 50 g, 0.36 mol) in toluene (500 mL) were heated 
to 110–115°C to remove the water by azeotropic distil-
lation. To this solution 2-(2-chloroethoxy)-acetic acid 
(50  g, 0.36  mol) was added at 50–60°C and reheated to 
110–115°C for 18  h. Reaction mass was cooled and fil-
tered. Filtrate was concentrated to get residue, residue 
was recrystallized using isopropyl alcohol (300  mL) to 
afford yellow solid of compound 18. Yield: 47 g (50.0%). 
M.P.: 101–104°C. 1H NMR (DMSO-d6, 400 MHz): δ 10.38 
(s, 1H), 8.22 (d, 2H), 7.91 (d, 2H), 4.22 (s, 2H), 3.82 (s, 
4H). Chemical purity by HPLC: 98.5%.
Preparation of 4‑(4‑nitophenyl)‑3‑morpholinone (19)
A solution of 2-(2-chloroethoxy)-N-(4-nitrophenyl) 
acetamide (18, 50 g, 0.19 mol), TBAB (3.5 g) and sodium 
hydroxide (12  g, 0.3  mol) in dichloromethane (500  mL) 
was stirred at 25–35°C for 3 h. After completion of reac-
tion organic layer was washed with water (150  mL), 
organic layer was distilled out to provide residue which 
was crystallized in isopropyl alcohol (85  mL) to obtain 
yellow solid of compound 19. Yield: 37.8 g (90.0%). M.P.: 
148–152°C. 1H NMR (DMSO-d6, 400  MHz): δ 8.27 (d, 
2H), 7.77 (d, 2H), 4.27 (s, 2H), 4.0 (t, 2H, 3.86 (t, 2H). 
Chemical purity by HPLC: 99.5%.
Preparation of 4‑(4‑aminophenyl) morpholin‑3‑one (5)
A solution of 4-(4-nitophenyl)-3-morpholinone (19, 
100 g, 0.45 mol) with Pd–C (10% w/v, 50% wet, 2 g) and 
ammonium formate (170 g) in methanol (1,000 mL) was 
heated to 55–60°C for 90 min, upon completion of reac-
tion catalyst was filtered, filtrate was cooled to 5–10°C to 
precipitate compound 5, which was filtered and recrys-
tallized in water to get white solid of compound 5. Yield: 
65.0  g (75.0%). M.P.: 169–172°C. 1H NMR (DMSO-d6, 
400 MHz): δ 6.94 (d, 2H), 6.54 (d, 2H), 5.15 (d, 2H), 4.27 
(s, 2H), 3.90 (t, 2H), 3.56 (t, 2H). Purity by HPLC: 99.9%.
Chemical purity by HPLC: 99.9%.
Preparation of 2‑[(2R)‑2‑hydroxy‑3‑{[4‑(3‑oxomorpholin‑4‑yl)
phenyl]amino}propyl]‑1H‑isoindole‑1,3(2H)‑dione (7)
A suspension of 4-(4-aminophenyl)morpholin-3-one 
(5, 100  g, 0.52  mol) and 2-[(2S)-oxiran-2-ylmethyl]-1H-
isoindole-1,3(2H)-dione (6, 116.2 g, 0.57 mol) in isopro-
pyl alcohol (1,700 mL) and water (300 mL) was refluxed 
for 24 h. After completion of reaction (by HPLC), reac-
tion mass was cooled to 25–30°C, precipitated solid 7 
was filtered, washed with isopropyl alcohol (100  mL) 
and dried the solid under vacuum (650–700 mm/Hg) at 
50–55°C for 6  h to afford 7 as light yellow to off white 
colored solid. Yield: 196.8  g (96.0%). MS m/z: 395.9 
(M+ +  1). 1H NMR (DMSO-d6, 400  MHz): δ 2.98–3.04 
(m, 1H), 3.13–3.19 (m, 1H), 3.68–3.57 (m, 4H), 4.02–
3.91 (m, 3H), 4.13 (s, 2H), 5.16 (d, J = 5.2 Hz, 1H), 5.65 
(t, J  =  6.4  Hz, 1H), 6.61 (d, J  =  8.8  Hz, 2H), 7.01 (d, 
J  =  8.8  Hz, 2H), 7.82–7.88 (m, 4H). Purity by HPLC: 




N–N-carbonyldiimidazole (CDI) (61.5  g, 0.38  mol) was 
added to a suspension of 7 (100 g, 0.25 mol) and potas-
sium carbonate (34.5  g, 0.25  mol) in dichloromethane 
(1,000 mL) at 25–30°C. Reaction mixture was maintained 
at 25–30°C for 5–6  h until completion of the reaction 
(by HPLC). Inorganic solid was filtered and washed with 
dichloromethane (200  mL). Filtrate was collected and 
concentrated to obtain the residue. The residue was fur-
ther slurried in tetrahydrofuran (500 mL) at 50–55°C and 
cooled to 25–30°C, filtered the solid, washed the solid 
with tetrahydrofuran (50 mL) to furnish 8 as light yellow 
to off white solid. Yield: 101.1  g (95.0%). MS m/z: 422.0 
(M+ +  1). 1H NMR (CDCl3, 400  MHz): δ 3.75–3.72 (t, 
J =  5.2, 4.8  Hz, 2H), 4.0 (dt, 2H), 4.04 (t, 2H), 4.17 (dt, 
2H), 4.33 (s, 2H), 5.02 (m, 1H), 7.35–7.32 (d, J = 12 Hz, 
2H), 7.57–7.55 (d, J =  9.2  Hz, 2H), 7.77–7.74 (dd, 2H), 
7.89–7.78 (dd, 2H). Purity by HPLC: 99.80%. Chemical 




40% Methylamine solution (102  mL) was added to the 
solution of 8 (100  g, 0.23  mol) in methanol (1,000  mL) 
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at 25–30°C. Reaction mass was stirred at 60–65°C for 
4–6  h (completion of reaction monitored by HPLC). 
Reaction mass was cooled to 25–30°C, pH of reaction 
mass was adjusted to 1–2 using concentrated hydro-
chloric acid, precipitated solid was filtered, and washed 
with methanol (100 mL) to obtain crude 9. The obtained 
crude 9 was dissolved in mixture of methanol (800 mL) 
and dichloromethane (300 mL) by adjusting the pH 8–9 
of reaction using triethylamine at 25–30°C to achieve 
clear solution. Reaction mass was acidified to pH 2–3 
using concentrated hydrochloric acid to precipitate 9. 
Precipitated solid was filtered, washed with methanol 
(150 mL) and dried to furnish pure 9 as white solid. Yield: 
65.5 g (85.0%). MS m/z: 292.2 (M+ + 1). 1H NMR (D2O, 
400  MHz): δ 3.49 (d, 2H), 3.81–3.78 (t, J =  5.2, 4.8  Hz, 
2H), 3.97 (q, 1H), 4.11–4.08 (t, J = 4.8, 5.2 Hz, 2H), 4.40–
4.36 (t, J = 9.2, 6.8 Hz, 3H), 5.13 (m, 1H), 7.42–7.40 (d, 
J = 8.8 Hz, 2H), 7.61–7.58 (d, J = 8.8 Hz, 2H). Purity by 




thiophene‑2‑carboxamide (1) as per route‑A
4-Nitrophenyl 5-chlorothiophene-2-carboxylate (11, 
95  g, 0.33  mol) was added to a solution of 9 (100  g, 
0.30 mol) and triethylamine (46.2 g, 0.45 mol) in DMSO 
(600  mL) at 35–40°C. After completion of reaction (by 
HPLC) acetonitrile (200  mL) was added to the reaction 
mixture at 35–40°C. Reaction mixture was further heated 
up to 65°C, methanol (600  mL) was added to the reac-
tion mixture at 60–65°C. Reaction mixture was cooled 
to 25–30°C, the obtained solid was filtered, washed with 
methanol (100 mL), and dried under vacuum (700 mm/
Hg) for 4–5  h at 50–55°C to get pure rivaroxaban (1) 
as white to off white solid. Yield: 114.3  g (86.0%). MS 
m/z: 436.0 (M+ + 1). 1H NMR (DMSO-d6, 400 MHz): δ 
3.61–3.59 (t, J = 5.6 Hz, 2H), 3.72–3.69 (t, J = 5.2, 4.8 Hz, 
2H), 3.86–3.82 (q, 1H), 3.97–3.95 (t, J = 4.8, 5.6 Hz, 2H), 
4.21 (s, 2H), 4.16 (t, 1H), 4.87 (m, 1H), 7.2 (d, 1H), 7.42–
7.38 (d, 2H), 7.57–7.53 (d, 2H), 7.69 (d, 1H), 8.99–8.96 
(t, J =  4, 6  Hz, 1H). 3C NMR (DMSO-d6, 400  MHz): δ 
166.01, 160.85, 154.13, 138.48, 137.05, 136.51, 133.35, 
128.46, 128.15, 125.95, 118.31, 71.38, 67.75, 63.50, 49.03, 
47.44, 42.24. Elemental analysis: C, 52.5; H, 4.14; N, 9.65; 
S, 7.33. Purity by HPLC: 99.80%. Chiral purity by HPLC: 
99.95%. Chemical purity by HPLC: 99.80%. Chiral purity 
by HPLC: 99.95%.
Residual solvent by GC HS (ppm)
Methanol: 407, isopropyl alcohol: not detected, dichlo-
romethane: not detected, tetrahydrofuran: not detected, 
acetonitrile: 120, DMSO: 510, triethylamine: 20.
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